Evidence map›Paper›PMID 21051949›Full record

ArticleCell cycle (Georgetown, Tex.)2010

FGF inhibits the activity of the cyclin B1/CDK1 kinase to induce a transient G₂arrest in RCS chondrocytes.

Tri Tran, Victoria Kolupaeva, Claudio Basilico

Open access · bronzeAbstract read
In one paragraph

Article in Cell cycle (Georgetown, Tex.), 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
0.3field-weighted citation impact, top 42% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. A Network Map of FGF-1/FGFR Signaling System.Journal of signal transduction · 2014
    Review
  8. Article
  9. Review
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

Tri TranNYU School of Medicine, New York, USA.
Victoria Kolupaeva
Claudio Basilico
New York University · USNew York Proton Center · US

Funding

ROLE OF FGF SIGNALING IN BONE DEVELOPMENTR01DE013745 · NIDCR · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI BASILICO, CLAUDIO · 2001 to 2010
$3.2M
NIDCR NIH HHS DE013745NIDCR NIH HHS R01 DE013745
6 · The paper itself

Abstract

Fibroblast growth factors (FGFs) negatively regulate long bone development by inhibiting the proliferation of chondrocytes that accumulate in the G₁ phase of the cycle following FGF treatment. Here we report that FGF also causes a striking but transient delay in mitotic entry in RCS chondrocytes by inactivating the cyclin B1-associated CDK1(CDC2) kinase. As a consequence of this inactivation, cells accumulate in the G₂ phase of the cycle for the first 4-6 hours of the treatment. Cyclin B1/CDK1 activity is then restored and cells reach a G₁ arrest. The reduced cyclin B1/CDK1 activity was accompanied by increased CDK1 inhibitory phosphorylation, likely caused by increased activity and expression of the Myt1 kinase. FGF1 also caused dephosphorylation of the CDC25C phosphatase, that however appears due the inactivation of cyclin B1/CDK1 complex in the CDK1 feedback loop, and not the activation of specific phosphatases. the inactivation of the cyclin B1/CDK1 complex is a direct effect of FGF signaling, and not a consequence of the G₂ arrest as it can be observed also in cells blocked at mitosis by Nocodazole. The Chk1 and AtM/ATR kinase are known to play essential roles in the G₂ checkpoint induced by DNA damage/genotoxic stress, but inhibition of Chk1 or ATM/ATR not only did not prevent, but rather potentiated the FGF-induced G₂ arrest. Additionally our results indicate that the transient G₂ arrest is induced by FGF in RCS cell through mechanisms that are independent of the G₁ arrest, and that the G₂ block is not strictly required for the sustained G₁ arrest but may provide a pausing mechanism that allows the FGF response to be fully established.

Indexed as

AnimalsAntineoplastic AgentsAtaxia Telangiectasia Mutated Proteinscdc25 PhosphatasesCDC2 Protein KinaseCell Cycle ProteinsCell Line, TumorChondrocytesCyclin B1DNA-Binding ProteinsDown-RegulationFibroblast Growth Factor 1G2 PhaseMitosisNocodazolePhosphorylationAntineoplastic Agentsataxia telangiectasia and Rad3-related kinase, ratAtaxia Telangiectasia Mutated Proteinscdc25 PhosphatasesCDC2 Protein KinaseCell Cycle ProteinsCyclin B1DNA-Binding ProteinsFibroblast Growth Factor 1Myt1 kinase, ratNocodazoleProtein KinasesProtein Serine-Threonine KinasesProtein-Tyrosine KinasesTumor Suppressor Proteins

Identifiers

PMID21051949
PMCPMC3055189
OpenAlexW1971794180

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.